CAR T-cell therapy for CD30-positive lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment that uses your own immune cells, modified to find and attack cancer cells that have a protein called CD30 on them. It may be an option if your lymphoma has come back or hasn't improved with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 75 years old.
- You have Hodgkin lymphoma or a type of non-Hodgkin lymphoma that is CD30-positive.
- Your cancer has returned or hasn't responded to previous treatments.
- You are generally well enough to carry out daily activities (performance status above 60%).
- You have adequate organ function (kidney, liver, and lungs).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.